Fortis Healthcare Reports 17.3% Revenue Growth in Q2 FY26, Driven by Strong Hospital Performance

Fortis Healthcare Limited , one of India's leading healthcare providers, has reported robust financial results for the second quarter of fiscal year 2026, with significant growth in both revenue and profitability.

Strong Revenue Growth

The company's consolidated revenue for Q2 FY26 stood at INR2,331.00 crores, marking a 17.3% increase compared to the same period last year. This growth was primarily driven by the hospital segment, which saw a 19.3% year-on-year increase in revenue to INR1,974.00 crores. The diagnostic business also contributed positively, with a 7.1% growth in net revenue to INR357.00 crores.

Improved Profitability

Fortis Healthcare's consolidated operating EBITDA surged by 28% to INR556.00 crores, with the EBITDA margin expanding to 23.9% from 21.9% in Q2 FY25. The hospital business reported an operating EBITDA of INR452.00 crores, showing a 150 basis points improvement in margin to 22.9%. The company's profit after tax before exceptional items increased by 20.7% to INR305.00 crores.

Key Operational Metrics

Metric	Performance
Hospital occupancy	Improved to 71% compared to 69% in Q1 FY26
Occupied beds	Increased by about 13% to 3,318 in Q2 FY26
Average Revenue Per Occupied Bed (ARPOB)	Rose by 5.8% to INR2.51 crores per annum
Oncology segment growth	29% year-on-year, increasing revenue contribution to 16.2%
Robotic surgeries	66% year-on-year increase
Revenue from medical travel	Grew 26% to INR169.00 crores, contributing 8.1% to total revenue

Expansion and Strategic Initiatives

Fortis Healthcare has been actively pursuing growth opportunities:

Entered a 15-year lease agreement for a 200-bed multi-specialty hospital in Greater Noida.
Signed an O&M agreement for a 550-bed greenfield super specialty hospital in Lucknow.
Acquired Shrimann Super Speciality Hospital in Jalandhar, adding 190 operational beds.
Entered into an O&M agreement with Gleneagles India to manage five hospitals and a clinic.
Added 550 operational beds in H1 FY26 through various initiatives.

Diagnostic Business Performance

The diagnostic arm, Agilus Diagnostics, reported a 7.3% increase in gross revenue to INR400.00 crores. The operating EBITDA margin for this segment improved to 26.1% from 21.5% in Q2 FY25.

Dr. Ashutosh Raghuvanshi, Managing Director and CEO of Fortis Healthcare, commented on the results: "We continue to witness a healthy growth momentum in Q2 FY26 and H1 of FY26. Both our business segments, Hospitals and Diagnostics, continue to perform well both in terms of revenue and margins."

With these positive results and ongoing expansion initiatives, Fortis Healthcare continues to strengthen its position in the Indian healthcare sector, focusing on both organic growth and strategic acquisitions to enhance its service offerings and market presence.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.69%	-5.96%	-15.09%	+35.32%	+43.11%	+564.83%

Fortis Healthcare , a leading Indian healthcare provider, has reported strong financial results for the second quarter of fiscal year 2026, demonstrating significant growth and improved profitability across its hospital and diagnostics businesses.

Financial Highlights

Fortis Healthcare delivered consolidated revenue of INR 2,331.00 crores in Q2 FY26, marking a 17.3% year-on-year increase. The company's performance was driven by robust growth in both its hospital and diagnostics segments:

Segment	Revenue (INR Crores)	Growth (YoY)
Hospital Business	1,974.00	19.3%
Diagnostics Business	357.00	7.1%

The company's operating EBITDA saw a substantial increase of 28% to INR 556.00 crores, with margins expanding to 23.9% from 21.9% in the previous year.

Hospital Business Performance

The hospital business, which accounts for 85% of Fortis Healthcare's consolidated revenue, showed impressive growth:

Occupancy improved to 71% from 69% in Q1 FY26
Average Revenue Per Occupied Bed (ARPOB) increased by 5.8% to INR 2.51 crores per annum
Oncology segment grew by 29% year-on-year, increasing its revenue contribution to 16.2%
Robotic surgeries increased by 66% year-on-year

Diagnostics Business (Agilus)

Agilus Diagnostics, the company's diagnostics arm, also reported strong performance:

Gross revenue grew by 7.3% to INR 400.00 crores
Operating EBITDA margin improved to 26.1% from 21.5% in Q2 FY25
Conducted 10.6 million tests during the quarter

Expansion and Strategic Initiatives

Fortis Healthcare continues to focus on growth and expansion:

Entered a 15-year lease agreement for a 200-bed multi-specialty hospital in Greater Noida
Signed an O&M agreement for a 550-bed greenfield super specialty hospital in Lucknow
Acquired Shrimann Super Speciality Hospital in Jalandhar, adding 190 operational beds
Added a total of 550 operational beds in H1 FY26

Management Commentary

Dr. Ashutosh Raghuvanshi, Managing Director and CEO of Fortis Healthcare, stated, "We continue to witness a healthy growth momentum in Q2 FY26 and H1 of FY26. Both our business segments, Hospitals and Diagnostics, continue to perform well both in terms of revenue and margins."

Outlook

With a strong balance sheet and improving operational metrics, Fortis Healthcare appears well-positioned for continued growth. The company's focus on expanding its hospital network, improving occupancy rates, and enhancing its diagnostics capabilities suggests a positive outlook for the coming quarters.